HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer - Wikidata - awgldk - TriplyDB

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

http://www.wikidata.org/entity/Q34638138

about

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients Gastric biomarkers: a global review State of the art management of metastatic gastroesophageal cancer HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing.Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force Treatment options in patients with metastatic gastric cancer: current status and future perspectives Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection.Chemoradiation for gastric cancer: controversies, updates and novel techniques.Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy.Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.The progress of targeted therapy in advanced gastric cancer HER2-positive gastric cancer.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Detection and Significance of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Adenocarcinoma Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications.Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis.Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis.HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.In Vivo HER2-Targeted Magnetic Resonance Tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature.Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.Immunohistochemical expression of HER2 in adenocarcinoma of the stomach.HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma.Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia.

P2860

Q21261244-048165FC-FFAC-48F5-89DD-0B4509BC07B6 Q26741859-B5B9D11C-7EEC-49AE-AFD0-7597CB445C38 Q26779217-31295040-4CF7-4AE0-B5EA-C6ADDEC8258A Q26780318-C395F95C-8C31-40DC-95D5-A738C85855F6 Q26796280-3D2EF225-0ACC-4AAE-9D62-BCEDBCB2D1C1 Q28078788-518BFF10-22B1-4CFF-867A-B655909C8F74 Q28082921-A5B7783D-F075-49D2-8E7F-5FD0A0BEEDA5 Q33764191-822655DE-32D4-4DE7-AC48-FCC0598087B9 Q34248282-3B8FDBB2-D283-404B-B7DF-198F79C086C8 Q34559419-E01A24E2-29F4-4850-A1CA-B1116E511536 Q34661367-E2B396B2-6B09-4DEF-988C-7F39388B381F Q35594687-9FE2EFBB-7BD9-4085-B1B3-8F13E06956C8 Q36235715-82B5AF77-CAA5-4CFC-BB33-AD7AB6A85DC6 Q36303653-26EBD5A0-39EE-4216-89D2-37221F79E57E Q36767781-EAFB37BE-EFD6-4E95-8036-EC40B194FD58 Q36778082-FD4E6BC9-3639-4BA6-9F62-FFA2CBA4BB1F Q36950483-C2667479-02ED-4277-B6AC-CDD918A7D559 Q37427269-2DBDC69A-F81E-41DE-9436-8DDE79E54473 Q37468290-9D1FDB80-E0B1-4243-9F28-EBA52CDE2FBC Q37708897-82E76B76-7A67-4923-9D1D-210580981854 Q41601800-B82A1BCB-898D-4332-A80D-06FA9DC40517 Q41721770-C41DA916-6B00-4580-AEA2-C537105671D0 Q43479667-414D3688-8B1E-43D0-9C38-5088AB0DE7EA Q47425148-C45874B4-0C9D-4FC1-A234-0DB76C287005 Q47764668-35ACC2C1-D8B9-4C25-A639-5D4DD3BFD5F5 Q50761028-DEC5FF51-EAF2-4CBB-837C-AE5FA46D353A Q51676931-3BA2C48E-5E65-4373-9379-B9583C26803F Q53134672-0BB5D657-94DE-4A74-9062-AA0895B4FFCC Q53424338-B7E2E744-5297-44F9-8F43-5E516E3024C9 Q53480719-681C94E3-76FD-4350-AEA2-44E6D86C62A9 Q53657591-101F7A04-9671-41BD-8552-D6A51006E864 Q54316753-EDC6BB9D-8102-4A49-99F2-B21AC5F43552 Q55175195-97E63AC3-B918-433C-9FAD-1C7FA959A455

P2860

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

http://www.wikidata.org/entity/Q34638138

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@ast

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@en

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@nl

type

label

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@ast

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@en

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@nl

prefLabel

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@ast

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@en

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@nl

P1433

Q34638138-E05C2D36-C3E6-42A1-92DF-5BA54B8CE02C

P1476

Q34638138-AB37A4B3-311D-4658-A010-7100CA43118F

P2093

Q34638138-6E631754-71CB-413B-963A-746D9AF4507F

Q34638138-77C95614-F8EE-433F-89E0-72D9475FE07D

Q34638138-867CE748-C211-4F95-887F-FA1D5C91F4B5

Q34638138-917BDDCE-0DEC-4E8C-BF06-B332CD9BCC56

Q34638138-98A9D757-A49F-4B5C-A329-98E9580CBF59

Q34638138-A906858D-8BE5-4F7C-959A-79EE7236E34A

Q34638138-CBD028B7-2E99-43BC-92C6-BABFE9E72075

Q34638138-E4199FBD-9F1A-4F5F-948D-DA4D628D75A7

P2860

Q34638138-0D75EDEA-7863-4B43-810B-230B8E23DB77

Q34638138-13E8608B-F71B-4DA4-A8BD-C11C6F05840A

Q34638138-1D5CCA63-2AF5-4E0E-88FD-B6B339D7720C

Q34638138-26365775-6636-4CE0-87D9-CF842596306C

Q34638138-3E6265CE-1495-43D8-B7F7-C1B9C259522D

Q34638138-6B15F237-07AE-4CCF-B0B1-B7C0124A8DC8

Q34638138-72668B09-47C6-4A8B-BA5E-E62C17FCE541

Q34638138-7A7998F5-CD0F-4BED-ADEA-906669971557

Q34638138-7F7EABAA-C254-46DC-9DF2-E5E7425D8327

Q34638138-8376738F-D664-443A-A8D9-6CEFD2C4F544

P304

Q34638138-600C3597-4CC7-4614-B105-527757F72076

P31

Q34638138-10611D1D-A002-4E91-86ED-CC4E2E84D2C0

P356

Q34638138-784D4587-9F95-4A80-8EB9-895A001D5B0F

P407

Q34638138-CCC55CCF-FD71-4B6D-8331-6E542BBCCF3D

P433

Q34638138-3CD7ABCE-0064-43CF-94A9-80AC970486D2

P478

Q34638138-07AEC5E2-F249-49C6-8479-ACAE5DE01AC1

P577

Q34638138-BF721418-3847-47DF-B6DE-C8EB7C512AC3

P5875

Q34638138-D5C893C1-1A6F-47C8-8136-EA8CE6F6A0BD

P698

Q34638138-67D858CD-5388-4723-B01D-65E33F5AE4F7

P932

Q34638138-DC17663E-9821-4953-9EE2-C272E85EB708

P356

JCLINPATH-2012-200774

P1433

Journal of Clinical Pathology

P1476

HER2/neu testing for anti-HER2 ...... d/or metastatic gastric cancer

@en

P2093

Alberto Arcediano

http://www.w3.org/2001/XMLSchema#string

Anabel Ballesteros

http://www.w3.org/2001/XMLSchema#string

Carlos Gómez-Martin

http://www.w3.org/2001/XMLSchema#string

Elena Garralda

http://www.w3.org/2001/XMLSchema#string

Fernando López-Ríos

http://www.w3.org/2001/XMLSchema#string

José Luis Rodríguez-Peralto

http://www.w3.org/2001/XMLSchema#string

M José Echarri

http://www.w3.org/2001/XMLSchema#string

Manuel Hidalgo

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

A study of HER2 gene amplification and protein expression in gastric cancer.

Emerging technologies for assessing HER2 amplification.

Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma.

Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.

P304

751-757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCLINPATH-2012-200774

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224925495

http://www.w3.org/2001/XMLSchema#string

P698

22569536

http://www.w3.org/2001/XMLSchema#string

P932

3410298

http://www.w3.org/2001/XMLSchema#string